Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Study sponsor: Candel Therapeutics, Inc. · CADL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2015-12Actual
Enrollment · participants52Actual
Source updated2024-04-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.